Caribou Biosciences, Inc. (CRBU)
0.519
+0.06
(+11.85%)
USD |
NASDAQ |
Oct 20, 16:00
0.5191
0.00 (0.00%)
After-Hours: 07:23
Caribou Biosciences Research and Development Expense (TTM) : 85.77M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.77M |
| March 31, 2026 | 94.52M |
| December 31, 2025 | 109.44M |
| September 30, 2025 | 116.09M |
| June 30, 2025 | 124.11M |
| March 31, 2025 | 131.90M |
| December 31, 2024 | 130.15M |
| September 30, 2024 | 130.97M |
| June 30, 2024 | 129.13M |
| March 31, 2024 | 120.15M |
| December 31, 2023 | 112.08M |
| September 30, 2023 | 106.53M |
| Date | Value |
|---|---|
| June 30, 2023 | 97.94M |
| March 31, 2023 | 94.02M |
| December 31, 2022 | 82.23M |
| September 30, 2022 | 71.60M |
| June 30, 2022 | 67.45M |
| March 31, 2022 | 57.20M |
| December 31, 2021 | 53.44M |
| September 30, 2021 | 50.35M |
| June 30, 2021 | 40.70M |
| March 31, 2021 | 35.95M |
| December 31, 2020 | 34.42M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Intellia Therapeutics, Inc. | 337.63M |
| Vir Biotechnology, Inc. | 471.79M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |